Markets:

Overview

News

Currencies

International

Treasuries

Biogen Idec (NQ:BIIB)

171.50 -4.24 (-2.41%)

Streaming Delayed Price Updated: 4:00 PM EST, Dec 16, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Biogen Idec

< Previous 1 2

...

21 22 23 24 25 26 27 28 29

...

56 57 Next >

Biogen Rises As 'Relatively Benign' FDA Documents Suggest An Alzheimer's Approval Is Near ↗

June 07, 2023

The FDA's advisors will consider the full approval of Leqembi on Friday.

Via Investor's Business Daily

Thinking Of Buying Boston Properties? Here Are The Properties And Tenants You'd Add To Your Portfolio ↗

June 07, 2023

When investors consider the purchase of a real estate investment trust (REIT), along with performance and dividends, they need to consider the properties and tenants that accompany that REIT. Several...

Via Benzinga

Biogen and Denali Realign Parkinson's Disease Research Priorities Amidst R&D Restructure ↗

June 05, 2023

Via Benzinga

$100 Invested In Biogen 15 Years Ago Would Be Worth This Much Today ↗

June 05, 2023

Via Benzinga

The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree ↗

June 02, 2023

Big Pharma is facing a patent cliff that could siphon off billions in revenue.

Via Investor's Business Daily

Biogen Unusual Options Activity For May 26 ↗

May 26, 2023

Via Benzinga

Analyst Ratings for Biogen ↗

May 23, 2023

Via Benzinga

If You Invested $1000 In This Stock 15 Years Ago, You Would Have $5,500 Today ↗

May 19, 2023

Via Benzinga

Biogen Hits Buy Zone On A Fresh Win In Alzheimer's Disease; Eli Lilly, Eisai Shares Jump ↗

June 01, 2023

The news also benefits Biogen's partner Eisai and rival Eli Lilly.

Via Investor's Business Daily

How Biohaven Is Coming 'Out Of Stealth Mode' — And Bullishly Extending A 4-Day Run ↗

June 01, 2023

Shares surged into and out of the company's R&D Day, which included a surprise.

Via Investor's Business Daily

Rotation Out Of Healthcare And Biotech Stocks: Age Of Disruption? ↗

May 30, 2023

A steady rotation out of biotech and healthcare stocks into the Nasdaq-100 large-cap tech stocks can be unnerving for portfolio managers.

Via Talk Markets

3 Biotech Stocks That Are Revolutionizing Healthcare in 2023 ↗

May 19, 2023

Here are three of the best biotech stocks to buy; each is on the verge of significant breakthroughs that may send the price higher.

Via InvestorPlace

1 Major Advantage Biogen May Have Over Pharma Giant Eli Lilly in a Multibillion-Dollar Market ↗

May 19, 2023

Analysts are bullish on Biogen's Alzheimer's drug, Leqembi, projecting it may generate over $10 billion in sales at its peak.

Via The Motley Fool

(BIIB) - Analyzing Biogen's Short Interest ↗

May 10, 2023

Via Benzinga

P/E Ratio Insights for Biogen ↗

May 08, 2023

Via Benzinga

Elliott Wave Technical Analysis: Biogen Inc. - Monday, May 8 ↗

May 08, 2023

Looking for longs on the way up into wave (3), as long as every downside pullback is a three wave move.

Via Talk Markets

Biogen Unusual Options Activity ↗

May 05, 2023

Via Benzinga

Analysts Say These 2 Mid-Cap Biotechs Have 2x Potential

May 18, 2023

These two mid-cap biotech companies are relatively established in their fields — but according to analysts, still have significant upside.

Via MarketBeat

Health Canada Accepts New Drug Submission for Lecanemab as Treatment for Early Alzheimer’s Disease

May 15, 2023

From Biogen Inc.

Via GlobeNewswire

Eli Lilly's Alzheimer's Drug Is Just Version 1.0. But It's Still On Track For Blockbuster Status, Analyst Says. ↗

May 15, 2023

An analyst says Lilly's donanemab could become a blockbuster in its second year on the market.

Via Investor's Business Daily

These 2 Pharma Stocks Might Face Off Soon -- but They Could Both Win ↗

May 14, 2023

There's no rule that says a market must have only one winner.

Via The Motley Fool

$1000 Invested In Biogen 15 Years Ago Would Be Worth This Much Today ↗

May 03, 2023

Via Benzinga

Why Eli Lilly Stock Is Bolting Higher Today ↗

May 03, 2023

Lilly's Alzheimer's disease candidate might be a best-in-class option for patients.

Via The Motley Fool

Biogen Unusual Options Activity For May 03 ↗

May 03, 2023

Via Benzinga

3 Reasons to Buy Biogen Stock (and 1 to Sell) ↗

May 12, 2023

The stock has been rallying but how it performs from here will likely depend on the fate of its Alzheimer's treatment, Leqembi.

Via The Motley Fool

Here’s What Eli Lilly’s Latest Clinical Win Means For Investors ↗

May 12, 2023

The biotech's prospects continue to get brighter.

Via The Motley Fool

Here's Why Eli Lilly's Alzheimer's Drug Could Be the Real Deal ↗

May 11, 2023

Eli Lilly stock may look expensive, but there's still plenty of value here for long-term investors.

Via The Motley Fool

Royalty Pharma Reaffirms FY23 Guidance Post Mixed Q1 Performance ↗

May 09, 2023

Via Benzinga

Analysts Say Eli Lilly's Donanemab In Alzheimer's Is Encouraging, Outline Potential Implications For Biogen ↗

May 04, 2023

Wednesday, Eli Lilly And Co (NYSE: LLY) announced positive results of the TRAILBLAZER-ALZ 2 Phase 3 study of

Via Benzinga

Another Sucess In Alzheimer’s Disease ↗

May 03, 2023

Eli Lily reported a successful phase III trial of donanemab in Alzheimer’s Disease. How does it differentiate from lecanemab and what does it mean for beta-amyloid treatments?

Via Talk Markets

< Previous 1 2

...

21 22 23 24 25 26 27 28 29

...

56 57 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.